• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 413464 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1413984899 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1413984899 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Ariad Pharmaceuticals Shares Climbing Higher, Up 4.8%

Published on Wed, 01/02/2013 - 11:28
By Robert Cotter

Ariad Pharmaceuticals (NASDAQ:ARIA) is a company whose shares are active, trading 4.8% higher to $20.10. The S&P is currently trading 1.8% higher to 1,452 and the Dow Jones Industrial Average is trading 1.8% higher to 13,339.

Ariad Pharmaceuticals share prices have moved between a 52-week high of $25.40 and a 52-week low of $12.26 and are now trading 64% above that low price at $20.10 per share. In the last five trading sessions, the 50-day moving average (MA) has fallen 1.7% while the 200-day MA has risen 0.5%.

Ariad Pharmaceuticals has overhead space with shares priced $20.10, or 30.4% below the average consensus analyst price target of $28.88. The stock should find resistance at its 50-day moving average (MA) of $21.57, as well as support at its 200-day MA of $19.27.

ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Shares of Reinsurance Group of America R...

Here are the top 5 stocks in the Reinsurance industry ranked by performance. We compil ...

Best Relative Performance in the Regiona...

We looked at the Regional Banks industry and measured relative performance to find the ...

Shares of Kansas City Southern Rank the ...

Below are the top five companies in the Railroads industry as measured by relative perf ...

Possible Bearish Inside Day Candle Patte...

Analysts have spotted a possible bearish inside day candle pattern in Universal Forest ...

Amtrust Financial Services has the Best ...

Here are the top 5 stocks in the Property & Casualty Insurance industry ranked by perfo ...

Relatively Good Performance Detected in ...

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We co ...

Possible Bearish Inside Day Candle Patte...

Analyzing the price chart for Intercontinental Hotels Group (NYSE:IHG) has revealed a ...

Shares of Ocwen Financial Underperformed...

Here are 5 stocks in the Thrifts & Mortgage Finance industry ranked by performance. We ...